<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01823133</url>
  </required_header>
  <id_info>
    <org_study_id>LG-GSCL001</org_study_id>
    <nct_id>NCT01823133</nct_id>
  </id_info>
  <brief_title>Study for Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Rosuvastatin</brief_title>
  <official_title>A Randomized, Open Label Crossover Study to Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Rosuvastatin in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the pharmacokinetic drug interactions between gemigliptin and rosuvastatin in
      healthy subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 72 hour post dose</time_frame>
    <description>to evaluate Cmax of gemigliptin and rosuvastatin at steady state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>up to 72 hour post dose</time_frame>
    <description>to evaluate AUCt of gemiglipin, rosuvastatin, and metabolite LC15-0636, N-desmethylrosuvastatin at steady state</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>up to 72 hour post dose</time_frame>
    <description>to evaluate time of Cmax at steady state, gemiglipin, rosuvastatin, and metabolite LC15-0636, N-desmethylrosuvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin</measure>
    <time_frame>upto 72 hour post dose</time_frame>
    <description>to evaluate Cmin of gemigliptin and rosuvastatin at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2Î²</measure>
    <time_frame>upto 72 hour post dose</time_frame>
    <description>to evaluate half-life of gemiglipin, rosuvastatin, and metabolite LC15-0636, N-desmethylrosuvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>upto 72 hour post dose</time_frame>
    <description>to evaluate Cmax of metabolite LC15-0636, N-desmethylrosuvastatin at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>upto 72 hour post dose</time_frame>
    <description>to evaluate AUC of metabolite LC15-0636, N-desmethylrosuvastatin at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic ratio</measure>
    <time_frame>upto 72 hour post dose</time_frame>
    <description>to evaluate metabolic ratio of gemiglipin and rosuvastatin</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>gemigliptin only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple administrations of gemigliptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rosuvastatin only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple administrations of rosuvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gemigliptin and rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple administrations of gemigliptin and rosuvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemigliptin only</intervention_name>
    <description>gemigliptin 50mg qd on day 1~7</description>
    <arm_group_label>gemigliptin only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin only</intervention_name>
    <description>rosuvastatin 20mg qd on day 1~7</description>
    <arm_group_label>rosuvastatin only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemigliptin and rosuvastatin</intervention_name>
    <description>gemigliptin 50mg, rosuvastatin 20mg qd on day 1~7</description>
    <arm_group_label>gemigliptin and rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 20 to 45, healthy male subjects (at screening)

          -  BMI between 18 - 27 kg/m2 (at screening)

          -  Blood pressure SBP 90-140 mmHg, DBP 60-95 mmHg

          -  FPG 70-125mg/dL glucose level (at screening)

          -  Subject who totally understand the progress of this clinical trials, make decision by
             his free will, and signed a consent form to follow the

        Exclusion Criteria:

          -  Subject who has past or present history of any diseases following below.(liver
             including hepatitis virus carrier, kidney,
             Neurology,immunology,pulmonary,endocrine,hematooncology,cardiology,mental disorder.)

          -  Subject who had GI tract disease that influencable to drug absorption or(ulcer, acute
             or chronic pancreatitis) surgery.(appendectomy, hernioplasty are not included)

          -  Subject who had drug hypersensitivity reaction.(gemigliptin, rosuvastatin, aspirin,
             antibiotics)

          -  Subject who already admitted in other investigator product in 80 days

          -  Subject who had whole blood donation in 60 days, or component blood donation in 30
             days or transfusion in 30 days currently
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2013</study_first_submitted>
  <study_first_submitted_qc>March 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2013</study_first_posted>
  <last_update_submitted>August 27, 2013</last_update_submitted>
  <last_update_submitted_qc>August 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

